Targeted magnetic iron oxide nanoparticles for tumor imaging and therapy.
Magnetic iron oxide (IO) nanoparticles with a long blood retention time, biodegradability and low toxicity have emerged as one of the primary nanomaterials for biomedical applications in vitro and in vivo. IO nanoparticles have a large surface area and can be engineered to provide a large number of functional groups for cross-linking to tumor-targeting ligands such as monoclonal antibodies, peptides, or small molecules for diagnostic imaging or delivery of therapeutic agents. IO nanoparticles possess unique paramagnetic properties, which generate significant susceptibility effects resulting in strong T2 and T*2 contrast, as well as T1 effects at very low concentrations for magnetic resonance imaging (MRI), which is widely used for clinical oncology imaging. We review recent advances in the development of targeted IO nanoparticles for tumor imaging and therapy.
Peng
Xiang-Hong
XH
Department of Medical Oncology/Hematology, Emory University School of Medicine, Atlanta, GA 30322, USA.
Qian
Ximei
X
Mao
Hui
H
Wang
Andrew Y
AY
Chen
Zhuo Georgia
ZG
Nie
Shuming
S
Shin
Dong M
DM
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003287:Contrast Media; D016503:Drug Delivery Systems / Q000379:methods; D004574:Electromagnetic Fields; D005290:Ferric Compounds / Q000008:administration & dosage*; D006801:Humans; D007089:Image Enhancement / Q000379:methods; D008279:Magnetic Resonance Imaging / Q000379:methods*; D053758:Nanoparticles / Q000008:administration & dosage*; D009369:Neoplasms / Q000175:diagnosis* / Q000188:drug therapy*
D000970:Antineoplastic Agents; D003287:Contrast Media; D005290:Ferric Compounds; C000499:ferric oxide